Search the Newsreel

Sei Investments Co. Purchases Shares of 38,152 Celldex Therapeutics, Inc. $CLDX

Sei Investments Co. recently acquired a new stake of 38,152 shares in Celldex Therapeutics, Inc., valued at approximately $1.21 million. This comes as several other hedge funds have also adjusted their positions in the biopharmaceutical company. Celldex Therapeutics reported better-than-expected quarterly earnings and has …

Why Celldex Therapeutics (CLDX) Is Up 10.7% After Wider Losses And Barzolvolimab Phase 3 Progress

Celldex Therapeutics (CLDX) reported wider Q2 and first-half losses totaling US$73.5 million and US$152.19 million, respectively, yet its stock rose by 10.7%. This increase is attributed to positive Phase 1 data for bispecific antibody CDX-622 and continued Phase 3 progress for barzolvolimab, despite minimal …

HC Wainwright Issues Optimistic Forecast for CLDX Earnings

Quantinno Capital Management LP Buys 42,158 Shares of Celldex Therapeutics, Inc. $CLDX

Quantinno Capital Management LP significantly increased its stake in Celldex Therapeutics (NASDAQ:CLDX) by 178.7% in the first quarter, purchasing an additional 42,158 shares to own a total of 65,744 shares valued at $2.09 million. This move comes as institutional investors continue to adjust their …

Celldex Therapeutics (CLDX) Stock Looks Rich On Book Value But Strong On Returns

Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Celldex Therapeutics (CLDX) released its second quarter 2026 results on 6 August, reporting very limited revenue and a wider net loss. This places the stock's …

Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern?

Celldex Therapeutics, Inc. recently reported second-quarter 2026 results, with revenue falling to US$0.022 million and net loss widening to US$73.5 million, while loss per share from continuing operations increased to US$0.94. Over the first half of 2026, revenue slipped to just US$0.037 million as …

Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Celldex Therapeutics stock has more than doubled over the past year, yet its broader valuation checks lean expensive rather than cheap, which raises …

What Is Celldex Therapeutics (CLDX) Signaling With Its Mixed Pipeline Update?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Celldex Therapeutics (NasdaqCM:CLDX) reported updated clinical pipeline data, including positive Phase 1 results for bispecific antibody CDX-622. The company outlined progress on ongoing Phase 3 …

Celldex Therapeutics (NASDAQ:CLDX) Issues Earnings Results, Beats Estimates By $0.12 EPS

Celldex Therapeutics, Inc. Stock 12‑Month Price Target Raised to $58.07, Implies 40% Upside

The average 12-month price target for Celldex Therapeutics, Inc. (CLDX) stock has been raised from $57.07 to $58.07 by 15 analysts, with individual forecasts ranging from $38 to $100 per share. This new target suggests a potential upside of approximately 40% based on the …

Celldex Therapeutics Inc (CLDX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Barclays Forecasts Strong Price Appreciation for Celldex Therapeutics (NASDAQ:CLDX) Stock

Celldex Therapeutics earnings beat by $0.12, revenue fell short of estimates

Celldex Therapeutics, Inc. 2026: Revenue $22K, EPS ($0.94) — 10-Q Summary

Celldex Therapeutics, Inc. reported its financial results for the quarter ended 2026, with revenue of $22K and a diluted loss per share of ($0.94), resulting in a net loss of ($73.5M) due to ongoing investments in trials and manufacturing. The company highlighted clinical milestones, …

Celldex Reports Second Quarter Financial Results and Provides Corporate Update

Celldex reported its second-quarter 2026 financial results, highlighting ongoing Phase 3 studies for barzolvolimab in chronic spontaneous urticaria with topline data expected in Q3/Q4 2026, and actively enrolling patients for cold urticaria and symptomatic dermographism studies. The company also announced positive Phase 1 results …

Celldex Q2 FY26 net loss widens to $73.5 million; R&D expenses climb to $67.5 million

Celldex reported a wider net loss of $

Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q2 Revenue $0.0M

Celldex Therapeutics, Inc. (CLDX) announced its Q2 revenue was $0.0M, as detailed in an earnings flash from MarketScreener. The company, a clinical-stage biotechnology firm, focuses on developing antibody-based therapeutics for inflammatory, allergic, autoimmune, and other diseases. Recent news also included adjustments to price targets …

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex Therapeutics (CLDX) reported a Q2 loss of $0.94 per share, which was better than the Zacks Consensus Estimate of a $1.04 loss, but missed revenue estimates significantly, posting only $0.02 million against an expectation of $0.73 million. Despite the revenue miss, the company's …

Celldex Therapeutics (NASDAQ: CLDX) ramps barzolvolimab spend, raises $324M

Celldex Therapeutics earnings up next as Phase III data looms By Investing.com

Celldex Therapeutics is set to report its second-quarter earnings, with investors focusing on the timing of topline data from its pivotal Phase III EMBARQ-CSU studies, expected in September to October. Analysts project a loss of $1.06 per share on revenue of $803,000, and Wall …

Celldex Therapeutics stock hits 52-week high at $40.30 By Investing.com

Celldex Therapeutics stock reached a 52-week high of $40.30, showcasing significant investor confidence with an 86.85% increase over the past year. Despite this surge and a market capitalization of $3.16 billion, InvestingPro data suggests the stock is currently overvalued. The company faces mixed news, …

Celldex Therapeutics (CLDX) After Phase 2 Trial Results As Valuation Questions Come Into Focus

Celldex Therapeutics (CLDX) is under scrutiny following its Phase 2 clinical trial results for prurigo nodularis. The stock has seen significant momentum with strong share price returns over the last year, leading to questions about its valuation. While it trades at a discount compared …

Celldex Therapeutics Inc (CLDX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Celldex Therapeutics Inc (CLDX), noting its current valuation score of 6.88, which ranks 244 out of 385 in the Biotechnology & Medical Research industry. The company's P/E ratio is -8.92, indicating a position between its recent high …

Stempoint Capital LP Purchases New Shares in Celldex Therapeutics, Inc. $CLDX

Celldex Therapeutics Inc (CLDX) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial analysis of Celldex Therapeutics Inc (CLDX), highlighting its current financial score of 5.70, which ranks 328 out of 385 in the Biotechnology & Medical Research industry. The company's financial status is stable with low operating efficiency, marked by a …

Wells Fargo & Company Issues Positive Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock Price

CLDX|Celldex Therapeutics Inc|Price:35.660|Chg%:+0.380

This article provides a comprehensive stock analysis of Celldex Therapeutics Inc (CLDX) by TradingKey, detailing its stock score, financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. The company's fundamentals are considered healthy with significant growth potential, and it is deemed …

Celldex Therapeutics Inc (CLDX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Celldex Therapeutics Inc (CLDX), listing major shareholders such as Wellington Management Company, LLP and BlackRock Institutional Trust Company, N.A., along with their respective holdings and proportions. It also breaks down shareholder types, institutional shareholding trends over several …

Celldex Therapeutics, Inc. Revenue Breakdown – DUS:TCE2

Celldex Therapeutics, Inc. (DUS:TCE2) generated €1.32 million in revenue last year, primarily from its "Novel Therapeutics for Human Health Care" segment, a significant decrease from €6.78 million in the previous year. The United States was the company's largest regional contributor, matching the segment's revenue.

Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?

Celldex Therapeutics (CLDX) Stock May Trade At A Premium After A 59% Run

Celldex Therapeutics (CLDX) stock has seen a significant 59.5% return over the past year, leading to a valuation that appears expensive when considering market multiples and P/B ratio. The company's P/B ratio of 6.1x is higher than the broader biotech industry average, indicating a …

CELLDEX THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $70 FROM $78

Leerink Partners has decreased its target price for Celldex Therapeutics Inc. from $78 to $70. This change was reported by Reuters two days prior to the crawl date, indicating a potential re-evaluation of the company's financial outlook by the analyst firm.